Epigenetic dysregulation at the crossroad of women’s cancer

Rakesh Kumar, Aswathy Mary Paul, Pranela Rameshwar, M. Radhakrishna Pillai

Research output: Contribution to journalReview article

Abstract

An increasingly number of women of all age groups are affected by cancer, despite substantial progress in our understanding of cancer pathobiology, the underlying genomic alterations and signaling cascades, and cellular-environmental interactions. Though our understanding of women’s cancer is far more complete than ever before, there is no comprehensive model to explain the reasons behind the increased incidents of certain reproductive cancer among older as well as younger women. It is generally suspected that environmental and life-style factors affecting hormonal and growth control pathways might help account for the rise of women’s cancers in younger age, as well, via epigenetic mechanisms. Epigenetic regulators play an important role in orchestrating an orderly coordination of cellular signals in gene activity in response to upstream signaling and/or epigenetic modifiers present in a dynamic extracellular milieu. Here we will discuss the broad principles of epigenetic regulation of DNA methylation and demethylation, histone acetylation and deacetylation, and RNA methylation in women’s cancers in the context of gene expression, hormonal action, and the EGFR family of cell surface receptor tyrosine kinases. We anticipate that a better understanding of the epigenetics of women’s cancers may provide new regulatory leads and further fuel the development of new epigenetic biomarkers and therapeutic approaches.

Original languageEnglish (US)
Article number1193
JournalCancers
Volume11
Issue number8
DOIs
StatePublished - Aug 2019

Fingerprint

Epigenomics
Neoplasms
Cell Surface Receptors
DNA Methylation
Acetylation
Histones
Protein-Tyrosine Kinases
Methylation
Life Style
Age Groups
Biomarkers
RNA
Gene Expression
Growth
Genes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Keywords

  • Acetylation
  • Chromatin
  • Epitranscriptomics
  • Estrogen receptor signaling
  • Histones
  • Methylation
  • RNA methylation
  • Receptor tyrosine kinases
  • TET enzymes
  • Women cancer

Cite this

Kumar, Rakesh ; Mary Paul, Aswathy ; Rameshwar, Pranela ; Pillai, M. Radhakrishna. / Epigenetic dysregulation at the crossroad of women’s cancer. In: Cancers. 2019 ; Vol. 11, No. 8.
@article{9f7e3e71d30645388f02fc999d789484,
title = "Epigenetic dysregulation at the crossroad of women’s cancer",
abstract = "An increasingly number of women of all age groups are affected by cancer, despite substantial progress in our understanding of cancer pathobiology, the underlying genomic alterations and signaling cascades, and cellular-environmental interactions. Though our understanding of women’s cancer is far more complete than ever before, there is no comprehensive model to explain the reasons behind the increased incidents of certain reproductive cancer among older as well as younger women. It is generally suspected that environmental and life-style factors affecting hormonal and growth control pathways might help account for the rise of women’s cancers in younger age, as well, via epigenetic mechanisms. Epigenetic regulators play an important role in orchestrating an orderly coordination of cellular signals in gene activity in response to upstream signaling and/or epigenetic modifiers present in a dynamic extracellular milieu. Here we will discuss the broad principles of epigenetic regulation of DNA methylation and demethylation, histone acetylation and deacetylation, and RNA methylation in women’s cancers in the context of gene expression, hormonal action, and the EGFR family of cell surface receptor tyrosine kinases. We anticipate that a better understanding of the epigenetics of women’s cancers may provide new regulatory leads and further fuel the development of new epigenetic biomarkers and therapeutic approaches.",
keywords = "Acetylation, Chromatin, Epitranscriptomics, Estrogen receptor signaling, Histones, Methylation, RNA methylation, Receptor tyrosine kinases, TET enzymes, Women cancer",
author = "Rakesh Kumar and {Mary Paul}, Aswathy and Pranela Rameshwar and Pillai, {M. Radhakrishna}",
year = "2019",
month = "8",
doi = "10.3390/cancers11081193",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "8",

}

Epigenetic dysregulation at the crossroad of women’s cancer. / Kumar, Rakesh; Mary Paul, Aswathy; Rameshwar, Pranela; Pillai, M. Radhakrishna.

In: Cancers, Vol. 11, No. 8, 1193, 08.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Epigenetic dysregulation at the crossroad of women’s cancer

AU - Kumar, Rakesh

AU - Mary Paul, Aswathy

AU - Rameshwar, Pranela

AU - Pillai, M. Radhakrishna

PY - 2019/8

Y1 - 2019/8

N2 - An increasingly number of women of all age groups are affected by cancer, despite substantial progress in our understanding of cancer pathobiology, the underlying genomic alterations and signaling cascades, and cellular-environmental interactions. Though our understanding of women’s cancer is far more complete than ever before, there is no comprehensive model to explain the reasons behind the increased incidents of certain reproductive cancer among older as well as younger women. It is generally suspected that environmental and life-style factors affecting hormonal and growth control pathways might help account for the rise of women’s cancers in younger age, as well, via epigenetic mechanisms. Epigenetic regulators play an important role in orchestrating an orderly coordination of cellular signals in gene activity in response to upstream signaling and/or epigenetic modifiers present in a dynamic extracellular milieu. Here we will discuss the broad principles of epigenetic regulation of DNA methylation and demethylation, histone acetylation and deacetylation, and RNA methylation in women’s cancers in the context of gene expression, hormonal action, and the EGFR family of cell surface receptor tyrosine kinases. We anticipate that a better understanding of the epigenetics of women’s cancers may provide new regulatory leads and further fuel the development of new epigenetic biomarkers and therapeutic approaches.

AB - An increasingly number of women of all age groups are affected by cancer, despite substantial progress in our understanding of cancer pathobiology, the underlying genomic alterations and signaling cascades, and cellular-environmental interactions. Though our understanding of women’s cancer is far more complete than ever before, there is no comprehensive model to explain the reasons behind the increased incidents of certain reproductive cancer among older as well as younger women. It is generally suspected that environmental and life-style factors affecting hormonal and growth control pathways might help account for the rise of women’s cancers in younger age, as well, via epigenetic mechanisms. Epigenetic regulators play an important role in orchestrating an orderly coordination of cellular signals in gene activity in response to upstream signaling and/or epigenetic modifiers present in a dynamic extracellular milieu. Here we will discuss the broad principles of epigenetic regulation of DNA methylation and demethylation, histone acetylation and deacetylation, and RNA methylation in women’s cancers in the context of gene expression, hormonal action, and the EGFR family of cell surface receptor tyrosine kinases. We anticipate that a better understanding of the epigenetics of women’s cancers may provide new regulatory leads and further fuel the development of new epigenetic biomarkers and therapeutic approaches.

KW - Acetylation

KW - Chromatin

KW - Epitranscriptomics

KW - Estrogen receptor signaling

KW - Histones

KW - Methylation

KW - RNA methylation

KW - Receptor tyrosine kinases

KW - TET enzymes

KW - Women cancer

UR - http://www.scopus.com/inward/record.url?scp=85071774411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071774411&partnerID=8YFLogxK

U2 - 10.3390/cancers11081193

DO - 10.3390/cancers11081193

M3 - Review article

AN - SCOPUS:85071774411

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 8

M1 - 1193

ER -